Rohinitib is a Specific eIF4A Inhibitor Used for Acute Lymphoblastic Leukemia Research
eIF4A is an enzymatic core of the eIF4F complex and an indispensable effector of the mTORC1 pathway. In the first place, eIF4A is a popular target for cancer treatments. Due to the inhibitory effect to translation initiation, eIF4A represses the oncogenic activation of HSF1. Moreover, HSF1 is a factor...
CMLD012612 is a Potent Eukaryotic Initiation Factor 4A (eIF4A) Inhibitor
Small molecules show targeting the translation machinery that can be used for the research of cancer, viral infection, and neurodegeneration. In particular, a class of translation inhibitors that possess potent cytotoxic activity against tumor cells is in the development. In this article, we will introduce a potent eukaryotic initiation...
CMLD012073, an Amidino-Rocaglates, is a Potent eIF4A Inhibitor
The eukaryotic translation initiation factors 4A (eIF4A) is crucial for the assembly of the translationally active ribosome. Especially, the eIF4A is an RNA helicase that forms part of the machinery of translation initiation. Small molecules targeting the translation machinery show considerable promise in the treatment of a variety of...
Zotatifin is a Selective and Well-Tolerated eIF4A (Protein Biogenesis) Inhibitor
In this article, we will introduce a potent, selective, and well-tolerated eIF4A inhibitor, Zotatifin. It promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM). Zotatifin is able to induce the formation of a stable ternary complex [eIF4A-RNA-eFT226]. Additionally, it increases the residence time for...